Tandem Diabetes Care (Nasdaq:TNDM) announced positive study data for its artificial pancreas using Control-IQ technology. The study demonstrated improved blood sugar control in children ages 2-6 with type 1 diabetes. It evaluated an artificial … [Read More...] about Study backs Tandem Control-IQ artificial pancreas in young children
Main Content
Sponsored Content
Noble Leads with its User-Centered Design Strategy
By Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we do. Our patient-centered approach pushes us to fully … [Read More...] about Noble Leads with its User-Centered Design Strategy
Featured Posts
11 diabetes tech startups you need to know
The diabetes technology space is one that's always innovating. From continuous glucose monitoring to insulin pumps and the artificial pancreas, we've seen a lot. Companies are looking for all kinds of ways to make their mark in the world of … [Read More...] about 11 diabetes tech startups you need to know
FDA approves over-the-counter Narcan nasal spray
The FDA announced today that it approved Narcan 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter, nonprescription use. Narcan rapidly reverses the effects of opioid overdose and remains the standard treatment for such an … [Read More...] about FDA approves over-the-counter Narcan nasal spray
Surmodics targets FDA premarket approval for drug-coated balloon in Q4
Surmodics (Nasdaq:SRDX) announced today that it received formal feedback from the FDA related to its SurVeil drug-coated balloon (DCB). Eden Prairie, Minnesota-based Surmodics gave the FDA a proposed approach to submit an amended premarket … [Read More...] about Surmodics targets FDA premarket approval for drug-coated balloon in Q4
New Philips Virtual Care Management portfolio extends to diabetes
Philips (NYSE:PHG) announced today that it debuted its Philips Virtual Care Management portfolio of flexible solutions and services. The Amsterdam-based medtech giant aims to help health systems, providers, payers and employers connect with … [Read More...] about New Philips Virtual Care Management portfolio extends to diabetes
ViCentra now offers Kaleido insulin pump in the Netherlands
ViCentra recently announced that it made its Kaleido insulin pump system available for users in the Netherlands. Utrecht, the Netherlands-based ViCentra designed its insulin pump system as a small, light and accurate platform. The company says the … [Read More...] about ViCentra now offers Kaleido insulin pump in the Netherlands
This implantable drug delivery system is self-powered
Researchers at Shirley Ryan AbilityLab and Northwestern University developed technology that uses external light sources to trigger drug delivery. Yamin Zhang and Dr. Colin Franz of Shirley Ryan and John Rogers of Northwestern led the research … [Read More...] about This implantable drug delivery system is self-powered
Endogenex taps former Medtronic executive as CEO
Endogenex, developer of a procedure for treating type 2 diabetes, announced today that it appointed Stacey Pugh as its new CEO. Pugh's responsibilities at Minneapolis-based Endogenex include expanding the company's clinical initiatives evaluating … [Read More...] about Endogenex taps former Medtronic executive as CEO
Rani Therapeutics beats Street EPS estimates in Q4
Rani Therapeutics (Nasdaq:RANI) shares dipped on fourth-quarter results that just managed to beat the consensus EPS forecast. Shares of RANI fell 4.2% at $5.70 apiece in midday trading today. MassDevice's MedTech 100 Index — which includes stocks … [Read More...] about Rani Therapeutics beats Street EPS estimates in Q4
Access in parts of Canada expands for Dexcom G6 CGM
Dexcom (Nasdaq:DXCM) announced that all people with type 1 and type 2 diabetes in Manitoba, Canada, meet eligibility criteria for its G6 CGM. As of the company's announcement, Manitoba is the only province in Canada that does not require an … [Read More...] about Access in parts of Canada expands for Dexcom G6 CGM
Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring
Know Labs (NYSE:KNW) announced today that it established a scientific advisory board to accelerate development for its glucose monitoring devices. Seattle-based Know Labs expects the members to advise on algorithm refinement, device development, … [Read More...] about Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring
In case you missed it
- Vaccine patch maker Vaxess names former Sanofi exec as chief strategy officer
- Stevanato Group, Thermo Fisher to bring on-body drug delivery system to market
- Study backs Tandem Control-IQ artificial pancreas in young children
- Stevanato Group, Recipharm partner on pre-filled syringes for inhaled therapeutics
- Senseonics projects more than 20% growth in 2023
- Nemaura Medical to offer CGM-guided insulin dose titration care model
- Novo Nordisk to lower pre-filled insulin device prices by up to 75%
- Insulet to replace Silicon Valley Bank in the S&P 500
- The biggest medical device VC deals of 2022
- Study supports RenovoRx drug-device combo for treating pancreatic cancer
- Analysts receive update on Embecta insulin patch pump progress
- Bigfoot Biomedical takes next steps for its holistic diabetes management platform
- FDA clears Abbott FreeStyle Libre for automated insulin pump integration
- Expanded Medicare coverage for CGM to go into effect next month
- Bigfoot Biomedical wins FDA clearance for Bigfoot Unity Android app
Clinical Trials
Study backs Tandem Control-IQ artificial pancreas in young children
Tandem Diabetes Care (Nasdaq:TNDM) announced positive study data for its artificial pancreas using Control-IQ technology. The study demonstrated improved blood sugar control in children ages 2-6 with type 1 diabetes. It evaluated an artificial pancreas using the Tandem t:slim x2 insulin pump with Control-IQ technology. Results were published in the New England Journal of Medicine. […]
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
Study backs Medtronic next-gen MiniMed 780G insulin pump for type 1 diabetes
Medtronic (NYSE:MDT) announced today that one-year data backs the use of its next-generation MiniMed 780G automated insulin pump. The ADAPT study compared MiniMed 780 G against multiple daily injections of insulin with an intermittently scanned CGM. ADAPT, which included 82 subjects, marks the first multi-national, randomized controlled study comparing these methods. The study evaluated adults […]
Fractyl Health ‘encouraged’ by results from diabetes reversal study
Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl’s Revita-T2Di long-term, open-label cohort. Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational […]
Study backs digital diabetes program from Vida Health
Vida Health announced that a study of its digital health diabetes management program demonstrated improvements in multiple metrics. San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes. Participants enrolled in […]
